Published in Drug Week, October 8th, 2004
Cystic fibrosis is a disease involving severe fat mal-absorption due to pancreatic dysfunction that affects in excess of 100,000 patients worldwide. These patients suffer deficiencies in production of key digestive enzymes, and as a result fail to make use of important nutrients of their diet.
Arexis's study, which was conducted at Sahlgrenska University Hospital in Gothenburg, shows that if cystic fibrosis patients are supplemented with the enzyme BSSL...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.